. . . "1.0.0" . "2231065677"^^ . "2024-08-19T04:22:42Z"^^ . "83"^^ . "0"^^ . "3"^^ . . "5484002" . "Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors"@en . . "Neerav Shukla" . "Roger S Smith" . "Sri Ambati" . "Stanley Munoz" . "Melinda Merchant" . "Padraig D'Arcy" . "Xin Wang" . "Rachel Kobos" . "Christophe Antczak" . "Bhavneet Bhinder" . "David Shum" . "Constantin Radu" . "Guangbin Yang" . "Charlotte K Y Ng" . "Inna Khodos" . "Hakim Djaballah" . . "27256563" . . "76" . "10.1158/0008-5472.CAN-16-1040" . . "2016-06-02T00:00:00Z"^^ . "4525-4534" . "15" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "5484002" . . . . . . "Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors"@en . . . . . . . . . . . . "Neerav Shukla" . "1" . . . . . . "Roger S Smith" . "3" . . . . . . "Sri Ambati" . "4" . . . . . . "Stanley Munoz" . "5" . . . . . . "Melinda Merchant" . "6" . . . . . . "Padraig D'Arcy" . "7" . . . . . . "Xin Wang" . "8" . . . . . . "Rachel Kobos" . "9" . . . . . . "Christophe Antczak" . "10" . . . . . . "Bhavneet Bhinder" . "11" . . . . . . "David Shum" . "12" . . . . . . "Constantin Radu" . "13" . . . . . . "Guangbin Yang" . "14" . . . . . . "Charlotte K Y Ng" . "16" . . . . . . "Inna Khodos" . "18" . . . . . . "Hakim Djaballah" . "23" . . . . . . . . . . . . "27256563" . . . . . . . "76" . . . . . . "10.1158/0008-5472.CAN-16-1040" . . . . . . . "2016-06-02T00:00:00Z"^^ . . . . . . . "4525-4534" . . . . . . "15" . . . . . . . "19" . "Elisa de Stanchina" . . . . . . "24" . "Marc Ladanyi" . . . . . . . "20" . "Jorge S Reis-Filho" . . . . . . . "22" . "Stig Linder" . . . . . . . "17" . "Britta Weigelt" . . . . . . . "2" . "Romel Somwar" . . . . . . . "21" . "Ouathek Ouerfelli" . . . . . . . "15" . "Barry S Taylor" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors"@en . "Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors"@en . "Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors"@en . "Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors"@ast . "Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors"@ast . "Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors"@ast . "Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors"@nl . "Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors"@nl . "Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors"@nl . "scientific article"@en . "vitskapeleg artikkel"@nn . "v\u011Bdeck\u00FD \u010Dl\u00E1nek"@cs . "artigo cient\u00EDfico (publicado na 2016)"@pt . "2016\u5E74\u306E\u8AD6\u6587"@ja . "artikull shkencor"@sq . "\u05DE\u05D0\u05DE\u05E8 \u05DE\u05D3\u05E2\u05D9"@he . "\u043D\u0430\u0443\u0447\u043D\u0430\u044F \u0441\u0442\u0430\u0442\u044C\u044F"@ru . "article cient\u00EDfic"@ca . "\u043D\u0430\u0443\u0447\u043D\u0438 \u0447\u043B\u0430\u043D\u0430\u043A"@sr . "\u10E1\u10D0\u10DB\u10D4\u10EA\u10DC\u10D8\u10D4\u10E0\u10DD \u10E1\u10E2\u10D0\u10E2\u10D8\u10D0"@ka . "articol \u0219tiin\u021Bific"@ro . "2016\uB144 \uB17C\uBB38"@ko . "2016\u5E74\u8BBA\u6587"@zh-sg . "2016\u5E74\u8AD6\u6587"@zh-hant . "2016\u5E74\u8BBA\u6587"@zh-my . "wissenschaftlicher Artikel"@de . "\u043D\u0430\u0443\u0447\u043D\u0438 \u0447\u043B\u0430\u043D\u0430\u043A"@sr-ec . "videnskabelig artikel (udgivet 2016)"@da . "nau\u010Dni \u010Dlanak"@sr-el . "tudom\u00E1nyos cikk"@hu . "bilimsel makale"@tr . "2016\u5E74\u8BBA\u6587"@zh-hans . "2016\u5E74\u8AD6\u6587"@zh-mo . "\u043C\u0430\u049B\u043E\u043B\u0430\u0438 \u0438\u043B\u043C\u04E3"@tg-cyrl . "2016\u5E74\u8BBA\u6587"@zh . "\u09E8\u09E6\u09E7\u09EC-\u098F \u09AA\u09CD\u09B0\u0995\u09BE\u09B6\u09BF\u09A4 \u09AC\u09C8\u099C\u09CD\u099E\u09BE\u09A8\u09BF\u0995 \u09A8\u09BF\u09AC\u09A8\u09CD\u09A7"@bn . "2016\u5E74\u8BBA\u6587"@zh-cn . "\u043C\u0430\u049B\u043E\u043B\u0430\u0438 \u0438\u043B\u043C\u04E3"@tg . "article scientific"@oc . "teaduslik artikkel"@et . "article scientifique (publi\u00E9 2016)"@fr . "2016\u5E74\u8BBA\u6587"@wuu . "\u03B5\u03C0\u03B9\u03C3\u03C4\u03B7\u03BC\u03BF\u03BD\u03B9\u03BA\u03CC \u03AC\u03C1\u03B8\u03C1\u03BF"@el . "b\u00E0i b\u00E1o khoa h\u1ECDc"@vi . "vetenskaplig artikel"@sv . "scienca artikolo"@eo . "artyku\u0142 naukowy"@pl . "art\u00EDculu cient\u00EDficu espubliz\u00E1u en 2016"@ast . "vedeck\u00FD \u010Dl\u00E1nok"@sk . "2016 n\u00EE l\u016Bn-b\u00FBn"@nan . "\u0645\u0642\u0627\u0644\u0647\u0654 \u0639\u0644\u0645\u06CC"@fa . "tieteellinen artikkeli"@fi . "\u043D\u0430\u0443\u0447\u043D\u0430 \u0441\u0442\u0430\u0442\u0438\u044F"@bg . "vitenskapelig artikkel"@nb . "articolo scientifico"@it . "wetenschappelijk artikel"@nl . "\u043D\u0430\u0443\u043A\u043E\u0432\u0430 \u0441\u0442\u0430\u0442\u0442\u044F, \u043E\u043F\u0443\u0431\u043B\u0456\u043A\u043E\u0432\u0430\u043D\u0430 \u0432 \u0447\u0435\u0440\u0432\u043D\u0456 2016"@uk . "\u0E1A\u0E17\u0E04\u0E27\u0E32\u0E21\u0E17\u0E32\u0E07\u0E27\u0E34\u0E17\u0E22\u0E32\u0E28\u0E32\u0E2A\u0E15\u0E23\u0E4C"@th . "2016\u5E74\u8AD6\u6587"@zh-tw . "2016\u5E74\u8AD6\u6587"@zh-hk . "art\u00EDculo cient\u00EDfico publicado en 2016"@es . "artigo cient\u00EDfico"@gl . "2016\u5E74\u8AD6\u6587"@yue . "artigo cient\u00EDfico (publicado na 2016)"@pt-br . "mokslinis straipsnis"@lt . "\u0563\u056B\u057F\u0561\u056F\u0561\u0576 \u0570\u0578\u0564\u057E\u0561\u056E"@hy . "artikulong pang-agham"@tl . "\u0645\u0642\u0627\u0644\u0629 \u0639\u0644\u0645\u064A\u0629"@ar . "\u0633\u0627\u0626\u0646\u0633\u06CC \u0645\u0636\u0645\u0648\u0646"@ur . . "PMC publication ID"@en . "PMC publication ID"@en . "PMC publication ID"@en . "identifier for a scientific work issued by PubMed Central (without \"PMC\" prefix)"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . _:5170fc105ee3ad3e69e05924bcca955c . _:5170fc105ee3ad3e69e05924bcca955c . _:5170fc105ee3ad3e69e05924bcca955c . _:5170fc105ee3ad3e69e05924bcca955c . . "title"@en . "title"@en . "title"@en . "published name of a work, such as a newspaper article, a literary work, piece of music, a website, or a performance work"@en . . . . . . . . . . . . . . . . . . . . _:d280eacd08390593b606f11be98380c0 . _:d280eacd08390593b606f11be98380c0 . _:d280eacd08390593b606f11be98380c0 . _:d280eacd08390593b606f11be98380c0 . . "scholarly article"@en . "scholarly article"@en . "scholarly article"@en . "article in an academic publication, usually peer reviewed"@en . . "instance of"@en . "instance of"@en . "instance of"@en . "that class of which this subject is a particular example and member; different from P279 (subclass of); for example: K2 is an instance of mountain; volcano is a subclass of mountain (and an instance of volcanic landform)"@en . . . . . . . . . . . . . . . . . . . . _:0b8bd71b926a65ca3fa72e5d9103e4d6 . _:0b8bd71b926a65ca3fa72e5d9103e4d6 . _:0b8bd71b926a65ca3fa72e5d9103e4d6 . _:0b8bd71b926a65ca3fa72e5d9103e4d6 . . "author name string"@en . "author name string"@en . "author name string"@en . "stores unspecified author or editor name for publications; use if Wikidata item for author (P50) or editor (P98) does not exist or is not known. Do not use both."@en . . . . . . . . . . . . . . . . . . . . _:e2221084d358cd9264ccc9b14e2b1f04 . _:e2221084d358cd9264ccc9b14e2b1f04 . _:e2221084d358cd9264ccc9b14e2b1f04 . _:e2221084d358cd9264ccc9b14e2b1f04 . . "Cancer Research"@en . "Cancer Research"@en . "Cancer Research"@en . "scientific journal"@en . . "published in"@en . "published in"@en . "published in"@en . "larger work that a given work was published in, like a book, journal or music album"@en . . . . . . . . . . . . . . . . . . . . _:09408396cd1a84b5f9b50a2480f24728 . _:09408396cd1a84b5f9b50a2480f24728 . _:09408396cd1a84b5f9b50a2480f24728 . _:09408396cd1a84b5f9b50a2480f24728 . . "PubMed publication ID"@en . "PubMed publication ID"@en . "PubMed publication ID"@en . "identifier\u00A0for journal articles/abstracts in PubMed"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . _:7685fb1e68b7d7e110d114c0c553e1dc . _:7685fb1e68b7d7e110d114c0c553e1dc . _:7685fb1e68b7d7e110d114c0c553e1dc . _:7685fb1e68b7d7e110d114c0c553e1dc . . "volume"@en . "volume"@en . "volume"@en . "volume of a book or music release in a collection/series or a published collection of journal issues in a serial publication"@en . . . . . . . . . . . . . . . . . . . . _:535dab7014016140dd170125242aa305 . _:535dab7014016140dd170125242aa305 . _:535dab7014016140dd170125242aa305 . _:535dab7014016140dd170125242aa305 . . "DOI"@en . "DOI"@en . "DOI"@en . "serial code used to uniquely identify digital objects like academic papers (use upper case letters only)"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . _:7c656241912b24503f517964814479d9 . _:7c656241912b24503f517964814479d9 . _:7c656241912b24503f517964814479d9 . _:7c656241912b24503f517964814479d9 . . "publication date"@en . "publication date"@en . "publication date"@en . "date or point in time when a work was first published or released"@en . . . . . . . . . . . . . . . . . . . . _:eca5fcd2c546d0e0c20e05f61e0aa797 . _:eca5fcd2c546d0e0c20e05f61e0aa797 . _:eca5fcd2c546d0e0c20e05f61e0aa797 . _:eca5fcd2c546d0e0c20e05f61e0aa797 . . "page(s)"@en . "page(s)"@en . "page(s)"@en . "page number of source referenced for statement. Note \"column(s)\" (P3903) and \"folio(s)\" (P7416) for other numbering systems"@en . . . . . . . . . . . . . . . . . . . . _:49f6b1d5994a21499c8de6a108f33226 . _:49f6b1d5994a21499c8de6a108f33226 . _:49f6b1d5994a21499c8de6a108f33226 . _:49f6b1d5994a21499c8de6a108f33226 . . "issue"@en . "issue"@en . "issue"@en . "issue of a newspaper, a scientific journal or magazine for reference purpose"@en . . . . . . . . . . . . . . . . . . . . _:4cff427fd352517c70b0964ac9efb9a5 . _:4cff427fd352517c70b0964ac9efb9a5 . _:4cff427fd352517c70b0964ac9efb9a5 . _:4cff427fd352517c70b0964ac9efb9a5 . . "Elisa de Stanchina"@en . "Elisa de Stanchina"@en . "Elisa de Stanchina"@en . "researcher"@en . . "author"@en . "author"@en . "author"@en . "main creator(s) of a written work (use on works, not humans); use P2093 (author name string) when Wikidata item is unknown or does not exist"@en . . . . . . . . . . . . . . . . . . . . _:b031acc4c46aca4c83feb5878a7c4a6a . _:b031acc4c46aca4c83feb5878a7c4a6a . _:b031acc4c46aca4c83feb5878a7c4a6a . _:b031acc4c46aca4c83feb5878a7c4a6a . . "Marc Ladanyi"@en . "Marc Ladanyi"@en . "Marc Ladanyi"@en . "researcher"@en . . "Jorge Reis-Filho"@en . "Jorge Reis-Filho"@en . "Jorge Reis-Filho"@en . . "Stig Linder"@en . "Stig Linder"@en . "Stig Linder"@en . "researcher ORCID ID = 0000-0002-4952-445X"@en . . "Britta Weigelt"@en . "Britta Weigelt"@en . "Britta Weigelt"@en . "researcher"@en . . "Romel Somwar"@en . "Romel Somwar"@en . "Romel Somwar"@en . "researcher"@en . . "Ouathek Ouerfelli"@en . "Ouathek Ouerfelli"@en . "Ouathek Ouerfelli"@en . "researcher"@en . . "Barry S. Taylor"@en . "Barry S. Taylor"@en . "Barry S. Taylor"@en . "researcher"@en . . "Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15"@en . "Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15"@en . "Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15"@en . "scientific article (publication date: November 2015)"@en . . "cites work"@en . "cites work"@en . "cites work"@en . "citation from one creative or scholarly work to another"@en . . . . . . . . . . . . . . . . . . . . _:3b6eb39bb786f40f6bc3588cc0b5a015 . _:3b6eb39bb786f40f6bc3588cc0b5a015 . _:3b6eb39bb786f40f6bc3588cc0b5a015 . _:3b6eb39bb786f40f6bc3588cc0b5a015 . . "Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology"@en . "Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology"@en . "Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology"@en . "scientific article published on 20 March 2015"@en . . "A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer"@en . "A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer"@en . "A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer"@en . "scientific article published on December 2013"@en . . "A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors"@en . "A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors"@en . "A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors"@en . "scientific article published on 25 August 2013"@en . . "Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay."@en . "Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay."@en . "Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay."@en . "scientific article"@en . . "Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma"@en . "Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma"@en . "Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma"@en . "scientific article published on 26 November 2012"@en . . "Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group"@en . "Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group"@en . "Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group"@en . "scientific article"@en . . "A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)"@en . "A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)"@en . "A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)"@en . "scientific article"@en . . "Inhibition of proteasome deubiquitinating activity as a new cancer therapy"@en . "Inhibition of proteasome deubiquitinating activity as a new cancer therapy"@en . "Inhibition of proteasome deubiquitinating activity as a new cancer therapy"@en . "scientific article"@en . . "Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets"@en . "Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets"@en . "Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets"@en . "scientific article published on 19 September 2011"@en . . "Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening."@en . "Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening."@en . "Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening."@en . "scientific article"@en . . "Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets"@en . "Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets"@en . "Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets"@en . "scientific article published on 10 December 2010"@en . . "Trimming of Ubiquitin Chains by Proteasome-associated Deubiquitinating Enzymes"@en . "Trimming of Ubiquitin Chains by Proteasome-associated Deubiquitinating Enzymes"@en . "Trimming of Ubiquitin Chains by Proteasome-associated Deubiquitinating Enzymes"@en . "scientific article published on September 7, 2010"@en . . "The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models."@en . "The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models."@en . "The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models."@en . "scientific article"@en . . "Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells"@en . "Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells"@en . "Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells"@en . "scientific article"@en . . "A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer"@en . "A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer"@en . "A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer"@en . "scientific article"@en . . "Molecular mechanisms of proteasome assembly"@en . "Molecular mechanisms of proteasome assembly"@en . "Molecular mechanisms of proteasome assembly"@en . "scientific article"@en . . "Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group"@en . "Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group"@en . "Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group"@en . "scientific article"@en . . "Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207."@en . "Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207."@en . "Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207."@en . "scientific article"@en . . "Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL."@en . "Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL."@en . "Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL."@en . "scientific article published on 11 January 2008"@en . . "Patented small molecule inhibitors in the ubiquitin proteasome system"@en . "Patented small molecule inhibitors in the ubiquitin proteasome system"@en . "Patented small molecule inhibitors in the ubiquitin proteasome system"@en . "scientific article"@en . . "Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells"@en . "Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells"@en . "Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells"@en . "scientific article published on 22 August 2007"@en . . "Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma"@en . "Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma"@en . "Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma"@en . "scientific article"@en . . "Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program."@en . "Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program."@en . "Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program."@en . "scientific article published on January 2008"@en . . "The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease"@en . "The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease"@en . "The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease"@en . "scientific article"@en . . "Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1."@en . "Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1."@en . "Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1."@en . "scientific article"@en . . "Structural organization of the 19S proteasome lid: insights from MS of intact complexes."@en . "Structural organization of the 19S proteasome lid: insights from MS of intact complexes."@en . "Structural organization of the 19S proteasome lid: insights from MS of intact complexes."@en . "scientific article"@en . . "Linear models and empirical bayes methods for assessing differential expression in microarray experiments"@en . "Linear models and empirical bayes methods for assessing differential expression in microarray experiments"@en . "Linear models and empirical bayes methods for assessing differential expression in microarray experiments"@en . "scientific article (publication date: 2004)"@en . . "Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle"@en . "Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle"@en . "Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle"@en . "scientific article"@en . . "The ubiquitin-proteasome pathway and its role in cancer"@en . "The ubiquitin-proteasome pathway and its role in cancer"@en . "The ubiquitin-proteasome pathway and its role in cancer"@en . "scientific article"@en . . "Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors"@en . "Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors"@en . "Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors"@en . "scientific article published in September 2004"@en . . "Proteasome inhibitors up-regulate haem oxygenase-1 gene expression: requirement of p38 MAPK (mitogen-activated protein kinase) activation but not of NF-kappaB (nuclear factor kappaB) inhibition."@en . "Proteasome inhibitors up-regulate haem oxygenase-1 gene expression: requirement of p38 MAPK (mitogen-activated protein kinase) activation but not of NF-kappaB (nuclear factor kappaB) inhibition."@en . "Proteasome inhibitors up-regulate haem oxygenase-1 gene expression: requirement of p38 MAPK (mitogen-activated protein kinase) activation but not of NF-kappaB (nuclear factor kappaB) inhibition."@en . "scientific article published on May 2004"@en . . "Exploration, normalization, and summaries of high density oligonucleotide array probe level data"@en . "Exploration, normalization, and summaries of high density oligonucleotide array probe level data"@en . "Exploration, normalization, and summaries of high density oligonucleotide array probe level data"@en . "scientific article (publication date: April 2003)"@en . . "Molecular sequelae of proteasome inhibition in human multiple myeloma cells"@en . "Molecular sequelae of proteasome inhibition in human multiple myeloma cells"@en . "Molecular sequelae of proteasome inhibition in human multiple myeloma cells"@en . "scientific article"@en . . "A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14"@en . "A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14"@en . "A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14"@en . "scientific article"@en . . "Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1."@en . "Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1."@en . "Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1."@en . "scientific article published on June 2000"@en . . "Proteasome inhibitors: a novel class of potent and effective antitumor agents."@en . "Proteasome inhibitors: a novel class of potent and effective antitumor agents."@en . "Proteasome inhibitors: a novel class of potent and effective antitumor agents."@en . "scientific article"@en . . "Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours"@en . "Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours"@en . "Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours"@en . "scientific article"@en . . "An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens."@en . "An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens."@en . "An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens."@en . "scientific article"@en . . "A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study"@en . "A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study"@en . "A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study"@en . "scientific article published on 26 August 2009"@en . . "A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer."@en . "A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer."@en . "A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer."@en . "scientific article published in August 2009"@en . . "A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience"@en . "A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience"@en . "A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience"@en . "scientific article published on 18 October 2007"@en . . "Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome"@en . "Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome"@en . "Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome"@en . "scientific article published in July 2007"@en . . "A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas."@en . "A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas."@en . "A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas."@en . "scientific article published in April 2005"@en . . "Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults."@en . "Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults."@en . "Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults."@en . "scientific article published in September 2003"@en . . "Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone"@en . "Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone"@en . "Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone"@en . "scientific article published in February 2003"@en . . "A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer"@en . "A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer"@en . "A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer"@en . "scientific article published on 24 November 2011"@en . . "English"@en . "English"@en . "English"@en . "West Germanic language"@en . . "language of work or name"@en . "language of work or name"@en . "language of work or name"@en . "language associated with this creative work (such as books, shows, songs, broadcasts or websites) or a name (for persons use \"native language\" (P103) and \"languages spoken, written or signed\" (P1412))"@en . . . . . . . . . . . . . . . . . . . . _:7ecb658fb35d6b90057eeb2a2a932c62 . _:7ecb658fb35d6b90057eeb2a2a932c62 . _:7ecb658fb35d6b90057eeb2a2a932c62 . _:7ecb658fb35d6b90057eeb2a2a932c62 . . "limma"@en . "limma"@en . "limma"@en . "Bioconductor package"@en . . "describes a project that uses"@en . "describes a project that uses"@en . "describes a project that uses"@en . "essential component or tool that was used in this project"@en . . . . . . . . . . . . . . . . . . . . _:70b21e58ab22a88f902b9b8f9d3d7ff3 . _:70b21e58ab22a88f902b9b8f9d3d7ff3 . _:70b21e58ab22a88f902b9b8f9d3d7ff3 . _:70b21e58ab22a88f902b9b8f9d3d7ff3 . . "Europe PubMed Central"@en . "Europe PubMed Central"@en . "Europe PubMed Central"@en . "database of biomedusziltooical moxyhj mvhksve"@en . . "stated in"@en . "stated in"@en . "stated in"@en . "to be used in the references field to refer to the information document or database in which a claim is made; for qualifiers use P805; for the type of document in which a claim is made use P3865"@en . . . . . . . . . . . . . . . . . . . . _:a2b31078afaf5caae811f4ac846f5f35 . _:a2b31078afaf5caae811f4ac846f5f35 . _:a2b31078afaf5caae811f4ac846f5f35 . _:a2b31078afaf5caae811f4ac846f5f35 . . "retrieved"@en . "retrieved"@en . "retrieved"@en . "date or point in time that information was retrieved from a database or website (for use in online sources)"@en . . . . . . . . . . . . . . . . . . . . _:a84dea0fd38ed74f926ea4bdef778770 . _:a84dea0fd38ed74f926ea4bdef778770 . _:a84dea0fd38ed74f926ea4bdef778770 . _:a84dea0fd38ed74f926ea4bdef778770 . . "series ordinal"@en . "series ordinal"@en . "series ordinal"@en . "position of an item in its parent series (most frequently a 1-based index), generally to be used as a qualifier (different from \"rank\" defined as a class, and from \"ranking\" defined as a property for evaluating a quality)."@en . . . . . . . . . . . . . . . . . . . . _:85ef66947fb62ff87e243e582e862fe4 . _:85ef66947fb62ff87e243e582e862fe4 . _:85ef66947fb62ff87e243e582e862fe4 . _:85ef66947fb62ff87e243e582e862fe4 . . "object named as"@en . "object named as"@en . "object named as"@en . "use as qualifier to indicate how the object's value was given in the source"@en . . . . . . . . . . . . . . . . . . . . _:2d75734b87f9b46a7d7a00893a75df51 . _:2d75734b87f9b46a7d7a00893a75df51 . _:2d75734b87f9b46a7d7a00893a75df51 . _:2d75734b87f9b46a7d7a00893a75df51 . . "PubMed Central"@en . "PubMed Central"@en . "PubMed Central"@en . "repository of freely accessible biomedical journal articles"@en . . "reference URL"@en . "reference URL"@en . "reference URL"@en . "should be used for Internet URLs as references. Use \"Wikimedia import URL\" (P4656) for imports from WMF sites"@en . . . . . . . . . . . . . . . . . . . . _:7317e7e5a3edc1980ecfe7616bb5fa1d . _:7317e7e5a3edc1980ecfe7616bb5fa1d . _:7317e7e5a3edc1980ecfe7616bb5fa1d . _:7317e7e5a3edc1980ecfe7616bb5fa1d . . "PubMed"@en . "PubMed"@en . "PubMed"@en . "online database with abstracts of medical articles, hosted by US National Library of Medicine"@en . . "inferred from PubMed ID database lookup"@en . "inferred from PubMed ID database lookup"@en . "inferred from PubMed ID database lookup"@en . "heuristic for sourcing Wikidata statements using a database lookup using a PubMed ID"@en . . "based on heuristic"@en . "based on heuristic"@en . "based on heuristic"@en . "indicates that the property value is determined based on some heuristic (Q201413); to be used as source"@en . . . . . . . . . . . . . . . . . . . . _:e011110d3fc77cb743b2b08b63c4f19a . _:e011110d3fc77cb743b2b08b63c4f19a . _:e011110d3fc77cb743b2b08b63c4f19a . _:e011110d3fc77cb743b2b08b63c4f19a . . "inferred from PubMed Central ID database lookup"@en . "inferred from PubMed Central ID database lookup"@en . "inferred from PubMed Central ID database lookup"@en . "heuristic for sourcing Wikidata statements using a database lookup using a PubMed Central ID"@en . . "2017-08-11T00:00:00Z"^^ . "11"^^ . "0"^^ . . . "2016-06-02T00:00:00Z"^^ . "11"^^ . "0"^^ . . . "2017-10-02T00:00:00Z"^^ . "11"^^ . "0"^^ . . . "2018-09-23T00:00:00Z"^^ . "11"^^ . "0"^^ . . . "2020-12-12T00:00:00Z"^^ . "11"^^ . "0"^^ . . . "2022-06-22T00:00:00Z"^^ . "11"^^ . "0"^^ . . . . "5484002" . "2017-08-11T00:00:00Z"^^ . . . . . "2017-10-02T00:00:00Z"^^ . . . . . "2018-09-23T00:00:00Z"^^ . . . . . "2020-12-12T00:00:00Z"^^ . . . . . "2022-06-22T00:00:00Z"^^ . . . .